Opinion

Published within

« | ... | 1560 | 1561 | 1562 | 1563 | 1564 | 1565 | 1566 | 1567 | 1568 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Billa: grabbing a share of the food-to-go market

Billa, the Rewe-owned supermarket chain, has opened its first Billa Box convenience store in Vienna, Austria, which will offer food and drink to go. The concept will compete directly with existing food-to-go operators, allowing the retailer to capture a new demographic of customers. The originality of the format places Billa at the forefront of the small convenience store market in the country.

Published By Datamonitor
16 Nov 2009
CommentWire
CommentWire

Bijou Brigitte: expansion plans in tough UK market

German costume jewelry specialist Bijou Brigitte has been growing rapidly. It anticipates further growth in its domestic market, but it is mostly looking internationally to support its ambition of 100 new stores per year. However, the UK accessories market is getting less attractive for new entrants, as clothing retailers increase their penetration of the market.

Published By Datamonitor
19 Mar 2007
CommentWire
CommentWire

Bighams: full steam ahead

Bighams, the ready-to-cook specialist, has clearly recognized that consumers are increasingly unwilling to trade quality for convenience. Consumers' prepared meal requirements are now more sophisticated and providers must offer more than ease and speed of preparation.

Published By Datamonitor
15 Jun 2004
Expert View
Expert View

Big Six will double profits - but politics is to blame

The UK's Big Six energy suppliers will double their profits over the next 12 months according to Ofgem's recent Supply Market Indicator report. The primary reason for this is a drop in wholesale gas prices.

Published By Datamonitor
05 Aug 2014
ResearchWire
ResearchWire

Big Pharma: turning to reformulation

Published By Datamonitor
13 Oct 2006
Expert View
Expert View

Big pharma: tightening the marketers' purse strings

According to new research pharmaceutical companies are investing more than ever to promote their drugs. Growth in promotional investment is thought to be increasing at a faster rate than growth in ethical sales. With this trend unlikely to continue because of economic constraint can the drug companies improve the impact of their marketing or do they face the prospect of slashing expenditure?

Published By Datamonitor
06 Dec 2002
CommentWire
CommentWire

Big pharma: the transatlantic investment divide

The top US and EU pharma companies differ significantly in organic growth and asset allocation. From 1997-2001, US pharmaceutical companies saw greater ethical sales growth and higher cashflow than their EU counterparts - and re-invested a greater proportion of their revenues and cash in R&D and capital expenditure. This may leave them stronger going forward.

Published By Datamonitor
21 Aug 2002
CommentWire
CommentWire

Big pharma: SSRI risks could limit depression market

Leading depression drug makers such as Pfizer, GlaxoSmithKline, and Eli Lilly may face further scrutiny following the release of a new report stating that SSRI treatment increases suicidal tendencies in youths. While the report was keen to stress the positive risk/benefit ratio of the treatment, the suicidality data will no doubt cause alarm, further impacting upon the depression market.

Published By Datamonitor
25 Nov 2005
ResearchWire
ResearchWire

Big Pharma: sales growth by therapy area to 2011

Published By Datamonitor
14 Mar 2007
ResearchWire
ResearchWire

Big Pharma: rising R&D spend

Published By Datamonitor
28 Jul 2006

« | ... | 1560 | 1561 | 1562 | 1563 | 1564 | 1565 | 1566 | 1567 | 1568 | ... | » »|

No help is available.